The FDA’s recent move to grant emergency use authorization for convalescent plasma as a potential treatment for severe COVID-19 was met with controversy.
With many critics pointing out a lack of available data to support the treatment.
The FDA’s recent move to grant emergency use authorization for convalescent plasma as a potential treatment for severe COVID-19 was met with controversy.
With many critics pointing out a lack of available data to support the treatment.